Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

546 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial).
Bonaca MP, Wiviott SD, Sabatine MS, Buros J, Murphy SA, Scirica BM, Rifai N, Antman EM, Morrow DA. Bonaca MP, et al. Among authors: rifai n. Am J Cardiol. 2007 Feb 1;99(3):344-8. doi: 10.1016/j.amjcard.2006.08.035. Epub 2006 Nov 30. Am J Cardiol. 2007. PMID: 17261395 Clinical Trial.
Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy.
Wiviott SD, Cannon CP, Morrow DA, Murphy SA, Gibson CM, McCabe CH, Sabatine MS, Rifai N, Giugliano RP, DiBattiste PM, Demopoulos LA, Antman EM, Braunwald E. Wiviott SD, et al. Among authors: rifai n. Circulation. 2004 Feb 10;109(5):580-6. doi: 10.1161/01.CIR.0000109491.66226.26. Circulation. 2004. PMID: 14769678 Clinical Trial.
Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial.
Ridker PM, Morrow DA, Rose LM, Rifai N, Cannon CP, Braunwald E. Ridker PM, et al. Among authors: rifai n. J Am Coll Cardiol. 2005 May 17;45(10):1644-8. doi: 10.1016/j.jacc.2005.02.080. Epub 2005 Apr 25. J Am Coll Cardiol. 2005. PMID: 15893181 Free article. Clinical Trial.
Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
Ray KK, Cannon CP, Cairns R, Morrow DA, Rifai N, Kirtane AJ, McCabe CH, Skene AM, Gibson CM, Ridker PM, Braunwald E; PROVE IT-TIMI 22 Investigators. Ray KK, et al. Among authors: rifai n. J Am Coll Cardiol. 2005 Oct 18;46(8):1417-24. doi: 10.1016/j.jacc.2005.08.024. J Am Coll Cardiol. 2005. PMID: 16226164 Free article. Clinical Trial.
Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.
Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, Hsia J, Gersh BJ, Rifai N, Ridker PM, Pfeffer MA, Braunwald E; PEACE Investigators. Sabatine MS, et al. Among authors: rifai n. Circulation. 2007 Mar 27;115(12):1528-36. doi: 10.1161/CIRCULATIONAHA.106.649939. Epub 2007 Mar 19. Circulation. 2007. PMID: 17372173 Clinical Trial.
Clinical application of C-reactive protein across the spectrum of acute coronary syndromes.
Scirica BM, Morrow DA, Cannon CP, de Lemos JA, Murphy S, Sabatine MS, Wiviott SD, Rifai N, McCabe CH, Braunwald E; Thrombolysis in Myocardial Infarction (TIMI) Study Group. Scirica BM, et al. Among authors: rifai n. Clin Chem. 2007 Oct;53(10):1800-7. doi: 10.1373/clinchem.2007.087957. Epub 2007 Aug 23. Clin Chem. 2007. PMID: 17717132 Clinical Trial.
Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18.
Morrow DA, Sabatine MS, Brennan ML, de Lemos JA, Murphy SA, Ruff CT, Rifai N, Cannon CP, Hazen SL. Morrow DA, et al. Among authors: rifai n. Eur Heart J. 2008 May;29(9):1096-102. doi: 10.1093/eurheartj/ehn071. Epub 2008 Mar 12. Eur Heart J. 2008. PMID: 18339606 Free PMC article. Clinical Trial.
546 results